| Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial (NCT01010243) | University of Regensburg | 2009-10-01 |
| Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma (NCT00996957) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2009-10-01 |
| IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (NCT01053949) | University Hospital, Lille | 2009-10-01 |
| Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma (NCT00963820) | Millennium Pharmaceuticals, Inc. | 2009-10-01 |
| Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (NCT00983346) | University of Utah | 2009-10-01 |
| Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma (NCT00998270) | Tehran University of Medical Sciences | 2009-10-01 |
| Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients (NCT01394640) | Paolo Corradini | 2009-10-01 |
| Velcade Consolidation Bone Study (NCT01286077) | Janssen-Cilag International NV | 2009-09-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States (NCT00997386) | University of Arizona | 2009-09-01 |
| Connect® MM- The Multiple Myeloma Disease Registry (NCT01081028) | Celgene | 2009-09-01 |
| Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma (NCT01002703) | University of Leipzig | 2009-09-01 |
| Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma (NCT01029054) | University of Michigan Rogel Cancer Center | 2009-09-01 |
| Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma (NCT01160484) | Oncotherapeutics | 2009-09-01 |
| Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma (NCT00999830) | Innate Pharma | 2009-09-01 |
| Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders (NCT00973804) | National Cancer Institute (NCI) | 2009-08-25 |
| Host Dendritic Cells in Allograft Patients (NCT00935597) | Icahn School of Medicine at Mount Sinai | 2009-08-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation (NCT01066624) | The University of Texas Health Science Center at San Antonio | 2009-08-01 |
| Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 (NCT01206205) | University Hospital, Toulouse | 2009-08-01 |
| Busulfan in Multiple Myeloma (NCT00934232) | Guido Tricot | 2009-08-01 |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients (NCT00984828) | Shanghai Jiao Tong University School of Medicine | 2009-08-01 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor (NCT00967343) | Kiadis Pharma | 2009-08-01 |
| Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy (NCT00972959) | University of Athens | 2009-07-01 |
| Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects (NCT01091831) | Fondazione EMN Italy Onlus | 2009-07-01 |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma (NCT00948922) | H. Lee Moffitt Cancer Center and Research Institute | 2009-06-18 |
| Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation (NCT03402295) | Grupo de Estudos Multicentricos em Onco-Hematologia | 2009-06-15 |
| Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma (NCT00920855) | Cephalon | 2009-06-01 |
| Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects (NCT01018927) | University of Arkansas | 2009-06-01 |
| A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients (NCT00911859) | Janssen Research & Development, LLC | 2009-06-01 |
| Agaricus Blazei Murill in Patients With Multiple Myeloma (NCT00970021) | Ullevaal University Hospital | 2009-06-01 |
| Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma (NCT00925821) | Wuerzburg University Hospital | 2009-06-01 |
| Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? (NCT00892502) | Copenhagen University Hospital at Herlev | 2009-05-01 |
| Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma (NCT00892346) | Shanghai Jiao Tong University School of Medicine | 2009-05-01 |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY (NCT00809276) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-05-01 |
| Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant (NCT00901225) | Duke University | 2009-05-01 |
| Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG (NCT00899847) | Stanford University | 2009-05-01 |
| A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma (NCT00928486) | Celgene | 2009-04-28 |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma (NCT00916058) | Weill Medical College of Cornell University | 2009-04-23 |
| A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (NCT00884312) | Amgen | 2009-04-09 |
| Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma (NCT00778752) | Universitätsklinikum Hamburg-Eppendorf | 2009-04-01 |
| Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma (NCT00891384) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2009-04-01 |
| Exploratory Study on POL6326 in Stem Cell Mobilization (NCT01105403) | Polyphor Ltd. | 2009-04-01 |
| Panobinostat/Velcade in Multiple Myeloma (NCT00891033) | University of Arkansas | 2009-04-01 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (NCT00891137) | Cellerant Therapeutics | 2009-04-01 |
| Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients (NCT00872352) | Wolfson Medical Center | 2009-04-01 |
| A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma (NCT00920556) | Sirtris, a GSK Company | 2009-03-30 |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies (NCT00861510) | National Heart, Lung, and Blood Institute (NHLBI) | 2009-03-05 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies (NCT00837200) | Milton S. Hershey Medical Center | 2009-03-01 |
| Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT (NCT00861250) | Tampere University Hospital | 2009-03-01 |
| Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients (NCT00857324) | Tiziana Marangon | 2009-03-01 |
| Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma (NCT02800954) | Centre Hospitalier Universitaire, Amiens | 2009-02-23 |
| Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) (NCT00858234) | Merck Sharp & Dohme LLC | 2009-02-13 |
| Unrelated Umbilical Cord Blood (UBC)Transplantation (NCT01768845) | West Virginia University | 2009-02-03 |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma (NCT00847639) | Center for International Blood and Marrow Transplant Research | 2009-02-01 |
| Dose-escalation Study of Oral CX-4945 (NCT00891280) | Cylene Pharmaceuticals | 2009-02-01 |
| Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. (NCT01268774) | LEO Pharma | 2009-02-01 |
| Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction (NCT00790842) | PrECOG, LLC. | 2009-01-21 |
| Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (NCT01198457) | Bayer | 2009-01-01 |
| A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma (NCT00821249) | Pfizer | 2009-01-01 |
| Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma (NCT01530594) | King Faisal Specialist Hospital & Research Center | 2009-01-01 |
| A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma (NCT00872521) | Janssen-Cilag Pty Ltd | 2009-01-01 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L (NCT00807599) | Memorial Sloan Kettering Cancer Center | 2008-12-10 |
| Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma (NCT00547404) | Piramal Enterprises Limited | 2008-12-01 |
| Study of ENMD-2076 in Patients With Multiple Myeloma (NCT00806065) | CASI pharmaceuticals, Inc. | 2008-12-01 |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) (NCT00773747) | Merck Sharp & Dohme LLC | 2008-12-01 |
| Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy (NCT01132833) | UNC Lineberger Comprehensive Cancer Center | 2008-12-01 |
| Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma (NCT00821301) | Immune Control | 2008-12-01 |
| Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer (NCT00760370) | Vejle Hospital | 2008-12-01 |
| S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases (NCT00874211) | SWOG Cancer Research Network | 2008-12-01 |
| Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function (NCT00779922) | Poitiers University Hospital | 2008-11-01 |
| Skin Biopsies in Chemotherapy-Induced Neuropathy (NCT00956033) | Erasmus Medical Center | 2008-11-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant (NCT00909948) | Massachusetts General Hospital | 2008-11-01 |
| Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function (NCT00721734) | Amgen | 2008-11-01 |
| Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma (NCT00800059) | Ottawa Hospital Research Institute | 2008-11-01 |
| Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma (NCT00843310) | NYU Langone Health | 2008-11-01 |
| A Retreatment Study With Bortezomib for Multiple Myeloma (NCT01030302) | Janssen Korea, Ltd., Korea | 2008-11-01 |
| Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (NCT01255514) | Yonsei University | 2008-10-30 |
| Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma (NCT00777998) | Universitätsklinikum Hamburg-Eppendorf | 2008-10-14 |
| Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients (NCT01010880) | Biokine Therapeutics Ltd | 2008-10-01 |
| Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma (NCT00775502) | Kyowa Kirin Co., Ltd. | 2008-10-01 |
| Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma (NCT00792506) | Italfarmaco | 2008-10-01 |
| UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (NCT00869232) | University of Arkansas | 2008-10-01 |
| PHA-739358 for the Treatment of Multiple Myeloma (NCT00872300) | Nerviano Medical Sciences | 2008-10-01 |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT00729118) | Ohio State University Comprehensive Cancer Center | 2008-09-26 |
| Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging (NCT01780766) | Universitaire Ziekenhuizen KU Leuven | 2008-09-01 |
| Trial of Romidepsin and Bortezomib for Multiple Myeloma (NCT00765102) | Celgene | 2008-09-01 |
| A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma (NCT00725634) | AVEO Pharmaceuticals, Inc. | 2008-09-01 |
| Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma (NCT01096810) | Jagannath, Sundar, M.D. | 2008-09-01 |
| A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma (NCT00747123) | Celgene | 2008-09-01 |
| Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance (NCT02467010) | University Medical Center Groningen | 2008-09-01 |
| Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) (NCT00750815) | H. Lee Moffitt Cancer Center and Research Institute | 2008-09-01 |
| Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant (NCT01264315) | Fondazione EMN Italy Onlus | 2008-09-01 |
| Study of Natalizumab in Relapsed/Refractory Multiple Myeloma (NCT00675428) | Biogen | 2008-09-01 |
| Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma (NCT00570180) | University Health Network, Toronto | 2008-08-25 |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (NCT00689936) | Celgene | 2008-08-21 |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (NCT00761722) | Celgene | 2008-08-12 |